Efficacy and safety of panitumumab alone or in association with radiotherapy in unresectable cutaneous squamous cell carcinoma
| العنوان: | Efficacy and safety of panitumumab alone or in association with radiotherapy in unresectable cutaneous squamous cell carcinoma |
|---|---|
| المؤلفون: | A Grange-Prunier, M. Ehret, Florent Grange, Coralie Barbe, L. Visseaux, S. Servagi-Vernat, Anne Durlach, K. Hourbeigt, A. Petit, J. Sanchez |
| المساهمون: | Centre Hospitalier Universitaire de Reims (CHU Reims) |
| المصدر: | Journal of the European Academy of Dermatology and Venereology Journal of the European Academy of Dermatology and Venereology, Wiley, In press, ⟨10.1111/jdv.16465⟩ |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | medicine.medical_specialty, Skin Neoplasms, Cutaneous squamous cell carcinoma, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Best Overall Response, Dermatology, Gastroenterology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Panitumumab, ComputingMilieux_MISCELLANEOUS, Aged, Retrospective Studies, Aged, 80 and over, Chemotherapy, Performance status, business.industry, Antibodies, Monoclonal, Retrospective cohort study, 3. Good health, Radiation therapy, Infectious Diseases, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, business, medicine.drug |
| الوصف: | BACKGROUND The prognosis of unresectable cutaneous squamous cell carcinomas is very poor. OBJECTIVE To evaluate the efficacy and safety of panitumumab alone or in association with radiotherapy in the treatment of unresectable cutaneous squamous cell carcinoma. METHODS This was a monocentre retrospective study of all consecutive patients having received at least two courses of panitumumab, alone or in association with radiotherapy, between 2016 and 2019. The primary endpoint was the rate of best overall response, evaluated according to the RECIST 1.1 criteria. The secondary endpoints were the response and disease control rates at 6 weeks and 6 months, progression-free survival, overall survival and safety. RESULTS A total of 25 patients were included; their median age was 86 years, and 17 (86%) had a WHO performance status over 2. The best overall response rate was 52%, including four complete responses (16%) and nine partial responses (36%). All patients with complete response and five out of nine patients with partial response had received concurrent radiotherapy, in most cases in moderate to low doses ( |
| تدمد: | 1468-3083 0926-9959 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bc4c737589b9f322bd4b035bee1b5a1Test https://doi.org/10.1111/jdv.16465Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....7bc4c737589b9f322bd4b035bee1b5a1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14683083 09269959 |
|---|